-
Abbisko Enters Into An Exclusive License Agreement With Merck For Pimicotinib Conference Call (Chinese Session)
Title:
Abbisko Enters Into An Exclusive License Agreement With Merck For Pimicotinib Conference Call (Chinese Session)
Date/Time:
Tuesday December 05,
2023 09:00 AM
Click here to listen: Playback link
052023-12Abbisko Enters Into An Exclusive License Agreement With Merck For Pimicotinib Conference Call (Chinese Session)09:00 -
ESMO&AACR-NCI-EORTC Updated Data (Chinese Session)
Title:
ESMO&AACR-NCI-EORTC Updated Data (Chinese Session)
Date/Time:
Wednesday October 25,
2023 09:00 AM
Click here to listen: Playback link
252023-10ESMO&AACR-NCI-EORTC Updated Data (Chinese Session)09:00 -
2022 Interim Results Video Conference Call (English Session)
Title
2022 Interim Results Video Conference Call (English Session)
Date / Time
Tuesday August 23, 2022
08:00 am
Outside Mainland China：Click here for webcast
232022-082022 Interim Results Video Conference Call (English Session)08:00 -
FY21 Annual Results Conference Call (Chinese Session)
Title
FY21 Annual Results Conference Call (CHINESE SESSION)
Date / Time
Monday March 21, 2022
2:00 PM
REGISTRATION
ACCESS NUMBER： 400 810 8103 +86 10 57304352
MEETING PASSWORD： 776976(Attendee）
212022-03FY21 Annual Results Conference Call (Chinese Session)14:00 -
FY21 Annual Results Conference Call (English Session)
Title
FY21 Annual Results Conference Call (ENGLISH SESSION)
Date / Time
Monday March 21, 2022 10:00 am
Outside Mainland China：Click here for webcast
212022-03FY21 Annual Results Conference Call (English Session)10:00
Copyright © 2021 All rights reserved:Abbisko Therapeautics 沪ICP备17056565号